Biohaven Ltd NYSE:BHVN:

  • BIOHAVEN - COMPLETES ENROLLMENT IN RISE3 PIVOTAL PHASE 2/3 FOCAL EPILEPSY STUDY WITH OPAKALIM

  • BIOHAVEN - TOP-LINE RESULTS FROM RISE3 STUDY EXPECTED IN SECOND HALF OF 2026